Group 1 - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1][3] - Sportradar Group AG (SRAD) currently holds a Momentum Style Score of A, indicating strong potential for momentum investing [3][12] - The Zacks Rank for SRAD is 2 (Buy), suggesting it is positioned for outperformance in the market [4][12] Group 2 - SRAD shares have increased by 1.2% over the past week, while the Zacks Leisure and Recreation Products industry has decreased by 0.3% during the same period [6] - Over the last quarter, SRAD shares have risen by 29.57%, and by 161.57% over the past year, significantly outperforming the S&P 500's gains of 19.12% and 11.85% respectively [7] - The average 20-day trading volume for SRAD is 2,008,441 shares, indicating a bullish trend with above-average volume [8] Group 3 - In the past two months, three earnings estimates for SRAD have been revised upwards, increasing the consensus estimate from $0.31 to $0.33 [10] - For the next fiscal year, three estimates have moved higher while one has been revised downwards, reflecting a positive earnings outlook [10]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Gates Industrial (GTES) - Gates Industrial currently holds a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Performance Metrics - GTES shares have increased by 1.79% over the past week, while the Zacks Manufacturing - General Industrial industry has seen a slight decline of 0.01% [5] - Over the past month, GTES has shown a price change of 11.34%, outperforming the industry's 5.09% [5] - In the last quarter, GTES shares have risen by 40.62%, and over the past year, they have gained 39.82%, significantly outperforming the S&P 500's increases of 19.12% and 11.85% respectively [6] Trading Volume - The average 20-day trading volume for GTES is 1,566,129 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, one earnings estimate for GTES has increased, while none have decreased, raising the consensus estimate from $1.42 to $1.43 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions noted [9] Conclusion - Given the positive performance metrics and earnings outlook, GTES is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a strong candidate for near-term investment [11]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Caterpillar (CAT) - Caterpillar currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance [2][3] - The stock has shown a price increase of 2.03% over the past week, outperforming the Zacks Manufacturing - Construction and Mining industry, which rose by 0.66% [5] - Over the last month, CAT's shares increased by 13.13%, significantly higher than the industry's 4.7% performance [5] - In the past quarter, CAT shares rose by 38.97%, while the S&P 500 only increased by 16.04% [6] - Year-to-date, CAT's shares are up 12.22%, compared to the S&P 500's 12.11% [6] Trading Volume - The average 20-day trading volume for CAT is 2,584,124 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, 2 earnings estimates for CAT have been revised upwards, while 1 estimate was revised downwards, leading to an increase in the consensus estimate from $18.73 to $18.80 [9] - For the next fiscal year, 4 estimates have moved upwards with no downward revisions, indicating positive sentiment [9] Conclusion - Given the positive momentum indicators and earnings outlook, CAT is positioned as a strong buy candidate for investors seeking short-term gains [11]

Company Overview - LENZ Therapeutics, Inc. currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for investors [4] Performance Metrics - Over the past week, LENZ shares have increased by 6.64%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.16% [6] - In a longer time frame, LENZ's monthly price change is 13.09%, compared to the industry's 3.31% [6] - Over the past quarter, LENZ shares have surged by 26.99%, and over the last year, they have gained 49.13%, while the S&P 500 has only increased by 16.04% and 12.11%, respectively [7] Trading Volume - The average 20-day trading volume for LENZ is 330,002 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, one earnings estimate for LENZ has been revised upward, while none have been revised downward, leading to an increase in the consensus estimate from -$2.85 to -$2.81 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Given the strong performance metrics and positive earnings outlook, LENZ Therapeutics, Inc. is positioned as a promising investment opportunity with a Momentum Score of A [12]

Company Overview - ProKidney Corp. (PROK) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Price Performance - Over the past week, PROK shares have surged by 612.49%, significantly outperforming the Zacks Medical - Drugs industry, which increased by 1.75% [6] - In a longer timeframe, PROK's monthly price change is 292.82%, compared to the industry's 1.25% [6] - Over the past quarter, shares of PROK have increased by 349.87%, and they have gained 39.83% in the last year, while the S&P 500 has only moved 16.04% and 12.11%, respectively [7] Trading Volume - The average 20-day trading volume for PROK is 36,681,320 shares, which is a useful indicator of market interest and momentum [8] Earnings Outlook - In the past two months, one earnings estimate for PROK has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$0.52 to -$0.49 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Considering the strong price performance, trading volume, and positive earnings outlook, PROK is positioned as a promising momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]

Company Overview - Zevra Therapeutics (ZVRA) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for investors [3] Price Performance - ZVRA shares have increased by 28.64% over the past week, significantly outperforming the Zacks Medical - Drugs industry, which rose by 1.75% during the same period [5] - Over the past month, ZVRA's price change is 45.18%, compared to the industry's 1.25% [5] - In the last quarter, ZVRA shares have risen by 74.97%, and over the past year, they have gained 95.57%, while the S&P 500 has only moved 16.04% and 12.11%, respectively [6] Trading Volume - ZVRA's average 20-day trading volume is 1,122,698 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Estimates - In the past two months, three earnings estimates for ZVRA have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.31 to $1.35 [9] - For the next fiscal year, two estimates have also moved upwards, with no downward revisions during the same period [9] Conclusion - Given the strong momentum indicators and positive earnings outlook, ZVRA is positioned as a solid momentum pick for investors [11]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling even higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with Woodward (WWD) currently holding a Momentum Style Score of A [2] Group 2: Woodward's Performance Metrics - Woodward has a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance in the market [3] - Over the past week, WWD shares increased by 2.59%, while the Zacks Aerospace - Defense Equipment industry rose by only 0.09% [5] - In the last quarter, WWD shares surged by 44.91%, and over the past year, they are up 38.44%, significantly outperforming the S&P 500, which increased by 17.01% and 13.4% respectively [6] Group 3: Trading Volume and Earnings Outlook - WWD's average 20-day trading volume is 508,964 shares, which is a bullish indicator when combined with rising stock prices [7] - In the past two months, three earnings estimates for WWD have been revised upwards, increasing the consensus estimate from $6.21 to $6.28 [9] - The positive trend in earnings estimate revisions suggests a promising outlook for WWD [8]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the strategy of "buying high, hoping to sell even higher" [1] - The Zacks Momentum Style Score helps investors identify which metrics are effective for assessing momentum in stocks [2] Group 2: Watts Water (WTS) Analysis - Watts Water currently has a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4] - Over the past week, WTS shares increased by 3.8%, outperforming the Zacks Instruments - Control industry, which rose by 3.51% [6] - In the last quarter, WTS shares rose by 31.02%, and over the past year, they increased by 39%, compared to the S&P 500's gains of 19.67% and 12.87% respectively [7] Group 3: Trading Volume and Earnings Outlook - WTS has an average 20-day trading volume of 159,698 shares, indicating a bullish sign when combined with rising stock prices [8] - In the past two months, one earnings estimate for WTS increased, raising the consensus estimate from $9.28 to $9.42 [10] - The positive earnings outlook contributes to WTS's strong performance and momentum score [9][12]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Oric Pharmaceuticals, Inc. (ORIC) - ORIC currently holds a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Performance Metrics - Over the past week, ORIC shares increased by 4.75%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.88% [5] - In the last quarter, ORIC shares surged by 140.04%, and over the past year, they gained 19.27%, while the S&P 500 only increased by 19.67% and 12.87%, respectively [6] - The average 20-day trading volume for ORIC is 896,080 shares, indicating a bullish sentiment as the stock is rising with above-average volume [7] Earnings Outlook - In the past two months, three earnings estimates for ORIC have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$1.98 to -$1.74 [9] - For the next fiscal year, two estimates have also moved upwards, with no downward revisions during the same period [9] Conclusion - Given the positive performance metrics and earnings outlook, ORIC is positioned as a promising investment opportunity with a Momentum Score of B and a Zacks Rank of 2 (Buy) [11]